Welcome to LookChem.com Sign In|Join Free
  • or
((3aR,4R,6R,6aR)-6-(6-chloro-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl benzoate is a complex organic compound with a molecular formula of C19H17ClN4O5. It is a derivative of purine, a heterocyclic aromatic organic compound that is a component of nucleic acids. This specific compound features a tetrahydrofuro[3,4-d][1,3]dioxol-4-yl group, which is a cyclic structure containing both furan and dioxolane rings. The molecule also includes a benzoate group, which is a derivative of benzoic acid. The presence of a 6-chloro-9H-purin-9-yl group indicates that one of the hydrogen atoms in the purine ring has been replaced by a chlorine atom. ((3aR,4R,6R,6aR)-6-(6-chloro-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl benzoate is likely to be of interest in the field of medicinal chemistry, potentially as a precursor or intermediate in the synthesis of therapeutic agents.

3249-96-5

Post Buying Request

3249-96-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

3249-96-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 3249-96-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,2,4 and 9 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 3249-96:
(6*3)+(5*2)+(4*4)+(3*9)+(2*9)+(1*6)=95
95 % 10 = 5
So 3249-96-5 is a valid CAS Registry Number.

3249-96-5Downstream Products

3249-96-5Relevant academic research and scientific papers

Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents

Ikejiri, Masahiro,Saijo, Masayuki,Morikawa, Shigeru,Fukushi, Shuetsu,Mizutani, Tetsuya,Kurane, Ichiro,Maruyama, Tokumi

, p. 2470 - 2473 (2007)

Nucleoside analogues that have 6-chloropurine as the nucleobase were synthesized and evaluated for anti-SARS-CoV activity by plaque reduction and yield reduction assays in order to develop novel anti-SARS-CoV agents. Among these analogues, two compounds,

Novel Adenine Derivatives and the Use Thereof

-

, (2017/01/02)

The present invention relates to a novel adenine derivative and a pharmaceutical use thereof and, more specifically, to a novel adenine derivative having a structure of chemical formula 1 or a pharmaceutically acceptable salt thereof, and to a composition containing the same for preventing or treating degenerative brain disease. The novel adenine derivative and the pharmaceutically acceptable salt thereof according to the present invention are adenosine A3 receptor agonists, and have an action of inhibiting the migration (or infiltration) of inflammatory cells (microglia, macrophages, neutrophils, etc.), to disease areas and the activities thereof. In addition, the adenine derivative according to the present invention was verified to suppress and treat brain injury more remarkably when compared with the known adenosine A3 receptor agonists in a cerebral ischemia experimental model, exhibit a significant effect by drug administration 10 hours after cerebral infarction, and allow long-term survival in spite of brain injury due to cerebral ischemia, and thus can be useful as an agent for treating and preventing degenerative brain disease including stroke.(AA,BB,CC,DD) Chemical formula 5COPYRIGHT KIPO 2015

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 3249-96-5